Trump's pharma tariff will hit US first, says Hiranandani
Niranjan Hiranandani, founder of the Hiranandani Group, says the 100% US tariff on branded drugs will initially affect Americans, making medicines costlier there. He views the move as an opportunity for India to accelerate Atma Nirbhar Bharat. Hiranandani also highlighted GST cuts boosting economy, real estate, and affordable housing, predicting India's GDP growth could surpass 8-9% by mid-2026.